Recruiting

Drug Holiday

Sponsor:

National Bone Health Alliance

Code:

NCT02575157

Conditions

Osteoporosis

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

No intervention

Study Details

Brief summary:

Bisphosphonates (BP) are widely used in the prevention and treatment of osteoporosis in postmenopausal women and older men. Recently, there has been concern about the risk of adverse events after several years of using these agents. This has resulted in a publication from the Food and Drug Administration that suggested that, for many individuals, a holiday from bisphosphonates might be considered after 4-5 years of continuous use. In that publication there was little, if any, guidance on how clinicians should proceed after the holiday is initiated.

Conditions

Osteoporosis

Study ID

NCT02575157

Start date

Jun, 2015

Status verified date

Oct, 2015

Completion date

Jun, 2018

Anticipated

Primary completion date

Jun, 2016

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Postmenopausal women or males >50 years who have taken oral bisphosphonates (risedronate or alendronate) for five years or more, and in whom it is considered reasonable to initiate a holiday from the medication, or those who have been on a holiday for up to 3 months will be eligible for screening visit.
2. Subjects whose 25(0H) D level is above 30 ng/ml (subjects with 25(0H)D from 10-29 ng/ml may be included after supplementation and assessment of serum 25(0H)D) level is above 30 ng/ml.

-

Exclusion Criteria:

1. Current steroid treatment at or greater than 5 mg/day prednisone or equivalent.
2. The use of any other bone active medication other than risedronate or alendronate.
3. The use of teriparatide within the past 4 years.
4. A contra-indication to the discontinuation of bisphosphonate (e.g. fracture during treatment, extremely low t-score).
5. Subjects with fasting serum sCTX less than 100 pg/ml or greater than 300 pg/mL while taking bisphosphonates.
6. Failure to bring 25(0H)D serum level to 30 ng/ml or greater.
7. Metabolic bone disease other than osteoporosis.
8. Abnormal thyroid function (may be included when thyroid function is shown to be normal by TSH). Per local lab assessment.
9. Evidence of failure to adhere to bisphosphonate use -

Study Design

Enrollment

120 participants

Anticipated

Allocation

Non randomized

Intervention Model

Factorial

Interventions and Outcome Measures

Arms

no intervention: Discontinuing usage

Patients will discontinue use of bisphosphonates. Bone markers and BMD will be monitored until a need for reinitiation of treatment within 2-years is identified or needed.

Interventions

No intervention

No intervention

Primary outcome measure

  • Changes in bone turnover markers. [ Time Frame: 2 years ]
  • Changes in bone mineral density [ Time Frame: 2 years ]
  • Changes in trabecular bone score [ Time Frame: 2 years ]

Central Contacts and Locations

Central contacts

Locations

Taylor C. Wallace

Recruiting

Washington, District of Columbia, United States, 20036

Contacts

More Information

Sponsor

National Bone Health Alliance

Last update posted

Oct 14, 2015

Last verified

Oct, 2015

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by National Bone Health Alliance on 2015-10-14.